Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Value-Based Cancer Care

- PMLiVE

UCB’s bimekizumab shows continued improvement in hidradenitis suppurativa patients

There is currently only one approved biologic treatment for the inflammatory skin disease

- PMLiVE

The Considered appoints Bam Zahraie as chief experience officer

Zahraie was previously global innovation lead and associate managing director at Havas Health & You

- PMLiVE

The impact of pharma congresses on HCPs – virtual and in person

By Kieran Martinez

- PMLiVE

Webcast: Evolving Patient Journeys – How to generate deeper insights in a changing healthcare landscape

Watch part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years.

Inizio

Creating content for healthcare professionals

How to create content for health professionals

Catching the attention of time-strapped healthcare professionals is hard, but not impossible.

Springer Nature

- PMLiVE

Sanofi to cut US insulin prices by up to 78% in January 2024

The announcement follows similar moves by Novo Nordisk and Eli Lilly earlier this month

- PMLiVE

Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study

The treatment is already approved in the US for three disease states of prostate cancer

- PMLiVE

2023 PM Society Awards – winners announced

21GRAMS takes four Golds plus Best in Show AstraZeneca tops the pharma leader board

Next congress, please: making the most of virtual pharmaceutical congresses

By Aaron Hall

- PMLiVE

Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray

Royalty Pharma signed a deal for the programme in 2020 with Biohaven, which Pfizer has since acquired

- PMLiVE

Alzheimer’s Association report highlights need to improve patient-physician communication

Both individuals and primary care physicians reported a reluctance to address cognitive concerns

- PMLiVE

ABPI welcomes new NHS research guidance for integrated care systems

Included in the proposals are calls for a fixed rebate rate of 6.88% on all eligible NHS medicine sales to be paid by the industry

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links